References

Maron BJ, Towbin JA, Thiene G Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006; 113:1807-1816 https://doi.org/10.1161/CIRCULATIONAHA.106.174287
Cardiomyopathy UK. What is cardiomyopathy. 2018. http://www.cardiomyopathy.org/about-cardiomyopathy (accessed October 2022)
Wexler RK, Elton T, Pleister A, Feldman D. Cardiomyopathy: an overview. Am Fam Physician. 2009; 79:778-784
Cardiomyopathy UK. Dilated cardiomyopathy. http://www.cardiomyopathy.org/dilated-cardiomyopathy (accessed October 2022)
Cardiomyopathy UK. Hypertrophic cardiomyopathy. http://www.cardiomyopathy.org/about-cardiomyopathy/types-cardiomyopathy/hypertrophic-cardiomyopathy (accessed October 2022)
Cardiomyopathy UK. Restrictive cardiomyopathy. http://www.cardiomyopathy.org/about-cardiomyopathy/types-cardiomyopathy/restrictive-cardiomyopathy (accessed October 2022)
Prasad A. What is Takotsubo (stress) cardiomyopathy?. Eur Cardiol. 2015; 10:6-8 10.15420/ecr.2015.10.01.6
Sharkey SW, Windenburg DC, Lesser JR Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010; 55:333-341 https://doi.org/10.1016/j.jacc.2009.08.057
Chronic heart failure. National clinical guideline for diagnosis and management in primary and secondary care.Salisbury: Sarum Colourview Group; 2003
Elliott PM, Anastasakis A, Borger MA 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35:2733-2779 https://doi.org/10.1093/eurheartj/ehu284
Weissler-Snir A, Allan K, Cunningham K Hypertrophic cardiomyopathy-related sudden cardiac death in young people in Ontario. Circulation. 2019; 140:1706-1716 https://doi.org/10.1161/CIRCULATIONAHA.119.040271
O'Mahony C, Elliott P, McKenna W. Sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2013; 6:443-451 https://doi.org/10.1161/CIRCEP.111.962043
Sears SF, Shea JB, Conti JB. Cardiology patient page. How to respond to an implantable cardioverter-defibrillator shock. Circulation. 2005; 111:e380-382 https://doi.org/10.1161/CIRCULATIONAHA.104.508663
Elayi CS, Lusher S, Meeks Nyquist JL Interference between dental electrical devices and pacemakers or defibrillators: results from a prospective clinical study. J Am Dent Assoc. 2015; 146:121-128 https://doi.org/10.1016/j.adaj.2014.11.016
Ejection Fraction Heart Failure Measurement. http://www.heart.org (accessed October 2022)
Scottish Dental Clinical Effectiveness Programme. Antibiotic prophylaxis against infective endocarditis implementation advice 2018. http://www.sdcep.org.uk/media/qvpj2kfb/sdcep-antibiotic-prophylaxis-implementation-advice.pdf (accessed October 2022)
NICE. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. Clinical Guideline CG64. 2016. http://www.nice.org.uk/guidance/cg64 (accessed October 2022)
Jastak JT, Yagiela JA. Vasoconstrictors and local anesthesia: a review and rationale for use. J Am Dent Assoc. 1983; 107:(4)623-30 https://doi.org/10.14219/jada.archive.1983.0307
Akutsu A, Chiba T, Takahashi H Management of dental problems in patients with cardiovascular disease. J Am Dent Assoc. 1964; 68:333-342 https://doi.org/10.14219/jada.archive.1964.0104
Monheim LM. Local anaesthesia and Pain Control in Dental Practice, 4th edn. St Louis, MO, USA: CV Mosby; 1969
Oosterink FM, de Jongh A, Hoogstraten J. Prevalence of dental fear and phobia relative to other fear and phobia subtypes. Eur J Oral Sci. 2009; 117:(2)135-43 https://doi.org/10.1111/j.1600-0722.2008.00602.x
Craig DC, Boyle CA. Practical Conscious Sedation, 2nd edn. London: Quintessence; 2017
Hohner P, Reiz S. Nitrous oxide and the cardiovascular system. Acta Anaesthesiol Scand. 1994; 38:763-786 https://doi.org/10.1111/j.1399-6576.1994.tb03999.x
Eisele JH, Reitan JA, Massumi RA Myocardial performance and N2O analgesia in coronary-artery disease. Anesthesiology. 1976; 44:16-20 https://doi.org/10.1097/00000542-197601000-00003
Kawamura R, Stanley TH, English JB Cardiovascular responses to nitrous oxide exposure for two hours in man. Anesth Analg. 1980; 59:93-99
Tanaka M, Nishikawa T. Effects of nitrous oxide on baroreflex gain and heart rate variability. Acta Anaesthesiol Scand. 2004; 48:1163-1167 https://doi.org/10.1111/j.1399-6576.2004.00493.x
Scottish Dental Clinical Effectiveness Programme. Management of dental patients taking anticoagulant or antiplatelet drugs. 2022. http://www.sdcep.org.uk/media/ypnl2cpz/sdcep-management-of-dental-patients-taking-anticoagulants-or-antiplatelet-drugs-2nd-edition.pdf (accessed October 2022)
Gibson RM, Meechan JG. The effects of antihypertensive medication on dental treatment. Dent Update. 2007; 34:70-78 https://doi.org/10.12968/denu.2007.34.2.70

Cardiomyopathy and Dentistry

From Volume 49, Issue 10, November 2022 | Pages 795-802

Authors

Shazia Kaka

BDS, MJDF, RCSEng, MSc M Spec Care Dent

Specialty Registrar (STR) in Sedation and Special Care Dentistry, Oxfordshire Healthcare Foundation Trust, UK (shazia.kaka@kcl.ac.uk)

Articles by Shazia Kaka

Sarah Couzens

BDS, MFDS, PgCert DE, MSc M Spec Care Dent

Specialist in Special Care Dentistry; Department of Sedation and Special Care Dentistry, Guys and St Thomas NHS Foundation Trust, London

Articles by Sarah Couzens

Carole Ann Boyle

BDS, MMEDSci, MSND, RCSEd, FDS RCSEng, FDS RCSEd, FFDT, FDSRCSEd

Consultant in Special Care Dentistry; Department of Sedation and Special Care Dentistry, Guys and St Thomas NHS Foundation Trust, London

Articles by Carole Ann Boyle

Email Carole Ann Boyle

Abstract

This article considers the clinical implications of cardiomyopathy and how it impacts on the provision of oral care. Consideration is given to the management of pain and anxiety in this patient group and the provision of safe, effective care.

CPD/Clinical Relevance: With an increasingly ageing population, dentists should have the knowledge to safely assess and treat medically compromised patients.

Article

The cardiomyopathies are a diverse group of conditions that affect the shape, structure, and/or thickness of the heart muscle (the myocardium).1 They may affect anyone, at any age, with a current UK prevalence of approximately 1 in 500 people.2 The cause can be primary, with a genetic aetiology, or secondary to autoimmune, inflammatory, endocrine, neurological or infiltrative conditions.1,3 The prevalence of cardiomyopathy is rising, and those who are diagnosed are surviving longer. They are therefore more likely to present to the dental team.

Dental practitioners should have a basic awareness of the condition and know what questions to ask before treating or referring these patients onwards. Careful assessment is required to plan the use of local anaesthesia and sedation techniques.

There are five main types of cardiomyopathy and each affects the myocardium differently.

Register now to continue reading

Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Up to 2 free articles per month
  • New content available